Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease

NCT02332356 Phase 3 UNKNOWN

This randomized, controlled study aims to evaluate the impact of therapeutic intervention (step up) for the patients who are clinical remission with Magnetic Resonance Enterocolonography (MREC) active. In addition, to evaluate the impact of therapeutic step down for the patients who archived clinical and MREC remission. The primary endpoint is the rate of clinical remission at 104 weeks.

Details

Lead sponsor	Tokyo Medical and Dental University
Phase	Phase 3
Status	UNKNOWN
Enrolment	100
Start date	2014-09
Completion	2024-03

Conditions

• Crohn Disease

Interventions

• azathioprine or adalimumab and infliximab

Primary outcomes

• The rate of clinical remission at 104 weeks. — 104 weeks

Countries

Japan